-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Definium Therapeutics, Raises Price Target to $73

Benzinga·07/24/2026 15:01:07
语音播报
Piper Sandler analyst David Amsellem reiterates Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $48 to $73.